Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1

NCT01565200 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT01565200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01565200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1
Lead sponsor
Jules Bordet Institute
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2012
Completion date
December 31, 2022
Enrollment
90 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

her-2 positive breast cancer